Idiopathic Parkinson Disease Clinical Trial
Official title:
A Placebo-Controlled, Randomised, Double-Blind Trial to Assess the Safety and Efficacy of Intermittent Bilateral Intraputamenal (GDNF) Infusions Administered Via Convection Enhanced Delivery (CED) in Subjects With Parkinson&Apos;s Disease
A Placebo Controlled Randomised Trial of GDNF vs placebo
The study will require patients to undergo surgery to implant microcatheters precisely into
the brain. Patients will then attend clinic on a 2 weekly basis for infusions of a nerve
growth factor called GDNF or placebo. Specific tests will also be carried out at regular
intervals to assess your symptoms. All participants will undergo radio-isotope brain imaging
at the beginning and end of the study. Periodically patients will also be required to undergo
an MRI scan to assess the delivery of the study drug or placebo.
Patients who are considered likely to meet certain suitability criteria for this trial and
who provide fully informed consent to participate will have screening blood tests and
clinical assessments. As part of these assessments patients will be asked to stop their PD
medication overnight to allow us to assess the severity of their PD symptoms without the
benefit of medication on board. These assessments will answer if patients are eligible to
enter the trial. Some patients will not continue on with the trial following these
assessments. However, we will discuss with those patients alternative clinical care /
research options.
Patients that are felt to be eligible for the trial following these assessments will undergo
brain surgery performed under general anaesthetic. During the surgery 4 tiny plastic infusion
tubes will be inserted into the putamen area of the brain, 2 on either side of the brain (two
in each putamen). These tubes connect to a single metal port that will come out (exit) from
under the skin behind the ear. This port can be accessed as needed from the outside and will
allow GDNF or placebo infusions to be given every 4 weeks directly into the putamen part of
the brain without requiring additional surgery or piercing of the skin (see Figure 1).
Approximately 4 weeks after surgery patients will have an infusion of placebo / dummy drug
and an MRI to check the tubes and port system are working well enough to allow infusions of
either GDNF or placebo (further details below).
Patients will be required to attend NBT in order to have either GDNF or placebo infusions
given through the port and down the tiny plastic tubes into the putamen every 4 weeks for a
total of 9 months (10
infusions in total). Neither the patient nor the research team will know whether patients are
receiving GDNF or placebo / dummy infusions.
For some of these visits, patients will again be asked to stop their PD medication the night
before. By doing this, it will be possible to assess potential reversal of symptoms compared
with before the start of brain infusion treatments.During the course of this trial patients
will undergo positron emission tomography (PET) brain scans at another hospital on two or
three occasions to look for evidence of damaged brain cell recovery. This trial is therefore
time-consuming and this will be made clear to you before seeking your consent to participate.
We hope that this trial will help clarify whether GDNF does indeed have the potential to
reverse Parkinson's disease and restore parts of the brain. It must be understood, however,
that even if the trial yields positive results, further testing will be required in a larger
number of patients to meet the requirements of the health authorities prior to GDNF being
available over the long term or routinely.
Participation in this trial will involve some risks to patients. These risks are described in
detail later in this document and will be discussed with you before you give informed
consent. When the trial ends the information collected from participants will be used to
produce reports for scientific journals, and will be presented at scientific meetings so that
doctors and scientists around the world will better understand the potential brain restoring
and disease reversing effects of GDNF in PD.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04202757 -
Intravenous Plasma Treatment for Parkinson's Disease
|
Early Phase 1 | |
Not yet recruiting |
NCT05103618 -
Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA
|
Phase 2 | |
Completed |
NCT03700684 -
Voice Treatment for Parkinson's Disease
|
N/A | |
Completed |
NCT05027620 -
Feasibility of Motor-cognitive Home Training for Parkinson's Disease Using eHealth Technology
|
N/A | |
Recruiting |
NCT02960464 -
tDCS for Treatment of Depression in Parkinson's Disease
|
N/A | |
Completed |
NCT05699161 -
Adipose-derived Stromal Vascular Fraction Cells to Treat Parkinson
|
Phase 1/Phase 2 | |
Completed |
NCT03944785 -
Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)
|
||
Completed |
NCT01227265 -
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)
|
Phase 3 | |
Terminated |
NCT01215227 -
An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)
|
Phase 3 | |
Withdrawn |
NCT05832775 -
Study to Assess the Safety of MRx0029 or MRx0005 Compared to Placebo, in People With Parkinson's
|
Phase 1 | |
Active, not recruiting |
NCT02780895 -
Parkinsonian Brain Repair Using Human Stem Cells
|
Phase 1 | |
Recruiting |
NCT01860794 -
Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease
|
Phase 1/Phase 2 | |
Terminated |
NCT02393027 -
Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999
|
Early Phase 1 | |
Completed |
NCT02373072 -
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
|
Phase 1 | |
Completed |
NCT02445651 -
Physiological Effects of Nutritional Support in Patients With Parkinson's Disease
|
N/A | |
Completed |
NCT00437125 -
Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease
|
Phase 4 | |
Completed |
NCT02723396 -
Sleep, Awake & Move - Part I
|
||
Completed |
NCT00599339 -
Transdermal Rotigotine User Surveillance Study
|
||
Suspended |
NCT05471609 -
Sustained Release Oral Formulation for Treatment of Parkinson's Disease
|
Early Phase 1 | |
Completed |
NCT00160576 -
Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias
|
Phase 2 |